Journal of Pathology and Translational Medicine

Original Article

Insulin-like Growth Factor II mRNA-Binding Protein 3 Expression in Benign and Premalignant Lesions and Carcinomas of the Stomach.: Dae Hyun Song, Jung Wook Yang, Dong Chul Kim, Jong Sil Lee, Jeong Hee Lee, Sang Ho Jeong, Gyung Hyuck Ko; Korean J Pathol. 2011;45(4):379-385.; DOI: https://doi.org/10.4132/KoreanJPathol.2011.45.4.379

3,432 View
24 Download
2 Crossref

BACKGROUND
Recent studies have demonstrated that insulin-like growth factor II mRNA-binding protein 3 (IMP3) is expressed in malignant tumors of various organs but not in normal tissue. We investigated IMP3 expression in various benign lesions, premalignant lesions and carcinomas of the stomach.
METHODS
IMP3 immunohistochemical staining was performed on 24 benign gastric lesions, 24 gastric adenomas, and 322 gastric carcinomas.
RESULTS
IMP3 was not expressed in benign gastric lesions including adenomas with low-grade dysplasia, but was expressed in 17% of adenomas with high-grade dysplasia, and in 44% of carcinomas. As the carcinomas were in the advanced stage, they expressed IMP3 more frequently and strongly. Patients with IMP3-positive tumors had poorer survival than those with negative tumors.
CONCLUSIONS
IMP3 expression in gastric carcinoma may be related to tumor invasion and metastasis, and is an independent risk factor for poor prognosis.

Citations

Citations to this article as recorded by

IMP3, a Promising Prognostic Marker in Clear Cell Renal Cell Carcinoma
Ji Young Park, Misun Choe, Yuna Kang, Sang Sook Lee
Korean Journal of Pathology.2014; 48(2): 108. CrossRef
Role of combination of insulin-like growth factor II messenger RNA-binding protein 3 and claudin-1 immunostaining in differentiation between endometrial endometrioid carcinoma and uterine serous carcinoma
Maha M. Shamloula, Dareen A. Mohamed, Ayman El-Dorf
Egyptian Journal of Pathology.2013; 33(2): 237. CrossRef

First
Prev
Page of 1
Next
Last

Search